Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Published on: July 16, 2026, 5:22 p.m. | Source: The Economic Times
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003, a nasal spray. This move follows increased interest in psychedelic therapies and federal funding for research. The companies expect the deal to conclude in the third quarter of this year.
